ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Usefulness of in-silico prediction tools in the analysis of VWF genetic variants.

A. Woods1, J. Paiva2, D. Primrose3, M. Alberto4, A. Sanchez-Luceros5

1IMEX-CONICET-ANM, CABA, Ciudad Autonoma de Buenos Aires, Argentina, 2Academia Nacional de Medicina, CABA, Ciudad Autonoma de Buenos Aires, Argentina, 3Universidad de Moron, Moron, Buenos Aires, Argentina, 4National Academy of Medicine, Ciudad Autonoma de buenos aires, Ciudad Autonoma de Buenos Aires, Argentina, 5National Academy of Medicine, CABA, Ciudad Autonoma de Buenos Aires, Argentina

Abstract Number: PB0833

Meeting: ISTH 2022 Congress

Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies » VWF and von Willebrand Factor Disorders - Clinical Conditions

Background: To determine if disease-causing variants (DCV) observed in patients with von Willebrand disease (VWD) are related to their clinical and laboratory phenotypes, additional costly, labor-intensive and time-consuming experimental approaches are needed. In-silico prediction tools were designed to predict the pathogenicity of DCV on the structure and/or function of the resulting protein. However, their performance can vary greatly.

A reliable statistical ratefor evaluating in-silico methods is to calculate the Matthews correlation coefficient (MCC) for each method, which considers true positives/negatives, false positives/negatives. Values≥0.7 indicate very strong agreement between prediction and observation.

Aims: • To predict pathogenicity of DCVs found in our VWD2 patients, using in-silico methods.

• To calculate MCC for each method in predicting both pathogenicity in DCVs and neutrality in benign single nucleotide variants (SNVs).

Methods: Thirty-one DCVs, 35 synonymous and 17 non-synonymousSNVs, all located within exons17-28of VWF gene.

Thirty in-silico methods: I-Mutant; PolyPhen; SIFT; SIFT4G; Mutation-Taster; Provean; DANN; CADD; FunSeq2; Predict-SNP2; GWAVA; Eigen; EigenPC; PhD-SNP; BayesDel-addAF; BayesDel-noAF; LRT; M-Cap; MVP; ListS2; MetaLR; MetaRNN; MetaSVM; MutPred; Revel; Deogen2; Mutation-Assessor; FATHMM-MKL; FATHMM-XF; FATHMM.

Results: All DCVs were predicted as pathogenic: 25/31(80.6%) by ≥70% of in-silico methods; 4/31 (12.9%), by < 40% of methods.

Synonymous SNVs were predicted as benign: 34/35(97.1%) by >70% of methods; 1/35(2.8%) by 57.1% of methods.

Non-synonymous SNVs were predicted as benign: 12/17(70.6%) by>70% of methods; 2/17(11.7%) by < 20 of methods; p.Pro1601Thr: pathogenic by all methods.

DANN, CADD, and FunSeq2 showed MCC≥0.7; MVP and I-mutant, the worst MCC

(Fig.1).

Conclusion(s): DANN, CADD, FunSeq2 and Predict-SNP2 showed the best performance. In-silico methods might be excellent tools for supporting the classification of DCVs related to VWD.

Synonymous SNVs showed higher predictive accuracy than non-synonymous SNVs. p.Pro1601Thr as benign variant should be revised.

Not all the in-silico methods discriminate between DCVs and SNVs. This point needs further analysis to improve them.

Fig. 1.

Matthews correlation coefficient values of in-silico methods

To cite this abstract in AMA style:

Woods A, Paiva J, Primrose D, Alberto M, Sanchez-Luceros A. Usefulness of in-silico prediction tools in the analysis of VWF genetic variants. [abstract]. https://abstracts.isth.org/abstract/usefulness-of-in-silico-prediction-tools-in-the-analysis-of-vwf-genetic-variants/. Accessed October 2, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/usefulness-of-in-silico-prediction-tools-in-the-analysis-of-vwf-genetic-variants/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley